Finally, we further determined that BRGSF-CBC mice developed CRS-like traits upon injection of Blinatumomab, a bispecific T-cell engager targeting CD3 and CD19 (13), or myeloid-targeting anti-hVISTA (V-domain Ig Suppressor of T-cell Activation) antibody JNJ (14), both known to induce CRS in patients (15, 16). The gene discussed is CD19; the disease is congenital rubella syndrome.